Support women in science at Burnet Institute
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Hepatitis C, 2012 (15)
October, 2012 (1)
- Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs.
Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M
PLoS One. 2012 Oct; 7(10):e47335
August, 2012 (2)
- Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.
Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, Latour P, Jackson D, Brown L, Sparrow R, Prince M, Hart D, Loveland BE, Gowans EJ
PLoS One. 2012 Aug; 7(8):e39368 - The role of viral and host genetics in natural history and treatment of chronic HCV infection.
Doyle JS, Hellard ME, Thompson AJ
Best Pract Res Clin Gastroenterol. 2012 Aug; 26(4):413-427
June, 2012 (2)
- Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK
Med J Aust. 2012 Jun; 196(10):638-641 - Identifying newly acquired cases of hepatitis C using surveillance: a literature review.
Sacks-Davis R, Van Gemert C, Bergeri I, Stoové M, Hellard M
Epidemiol Infect. 2012 Jun; 140(11):1925-1934
May, 2012 (6)
- Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection.
Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV
AIDS. 2012 May; 26(13):1653-1661 - Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review.
Sacks-Davis R, Horyniak D, Grebely J, Hellard M
Int J Drug Policy. 2012 May; 23(3):176-184 - The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.
Vickerman P, Grebely J, Dore GJ, Sacks-Davis R., Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M
J Infect Dis. 2012 May; 205(9):1342-1350 - Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis.
Gouklani H, Bull RA, Beyer C, Coulibaly F, Gowans EJ, Drummer HE, Netter HJ, White PA, Haqshenas G
J Virol. 2012 May; 86(9):5080-5088 - Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.
Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ; on behalf of the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3))
Lancet Infect Dis. 2012 May; 12(5):408-414 - Impact of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection.
Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M, Dore GJ, Haber PS; on behalf of the ATAHC Study Group
J Gastroenterol Hepatol. 2012 May; 27(5):957-965
April, 2012 (3)
- Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group.
Hepatology. 2012 Apr; 55(4):1058-1069 - The role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.
McCaffrey K, Boo I, Tewierek K, Edmunds ML, Poumbourios P, Drummer HE
J Virol. 2012 Apr; 86(7):3961-3974 - Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.
Boo I, Tewierek K, Douam F, Lavillette D, Poumbourios P, Drummer HE
Biochem J. 2012 Apr; 443(1):85-94
March, 2012 (1)
- Modelling hepatitis C transmission over a social network of injecting drug users.
Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, Pattison PE, Robins GL
J Theor Biol. 2012 Mar; 297:73-87
Year
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
- 1997
- 1996
- 1995
- 1994
- 1993
- 1992
- 1991
- 1990
- 1989
- 1988
- 1987
- 1982
- 1981
- 1955
Program
- All
- Executive (0)
- Healthy Mothers, Healthy Babies (HMHB) (0)
- Towards Eliminating HIV (1)
- Strategic Funding & Partnerships Executive Team (0)
- Disease Elimination (0)
- Maternal, Child and Adolescent Health (1)
- Philanthropy and Supporter Engagement (0)
- Health Security and Pandemic Preparedness (0)
- Eliminate Malaria (2)
- Eliminate Tuberculosis (TB) (0)
- Finance (0)
- Healthy Ageing (0)
- Human Resources (0)
- Burnet Honorary Research Fellows (0)
- Research Support and Facilities (0)
- Harm Reduction (0)
- Information Technology (0)
- Burnet Vaccine Initiative (0)
- Laboratory Services (0)
- Eliminate Viral Hepatitis (0)
- Education & Training (0)
- Infectious Diseases Elimination (0)
- Support Services Group (0)
- Project Management and Quality Assurance Office (0)
- Marketing and Communications (0)
- International Operations (0)
- Commercialisation, Innovation and Industry Partnerships (0)
Discipline
- All
- Life Sciences (0)
- Public Health (0)
- International Development (0)
Research Theme
- All
- HIV and AIDS (43)
- Sexually Transmitted Infections (STIs) (15)
- Maternal and Child Health (5)
- Malaria (20)
- Immune Disease and Cancer (14)
- Hepatitis B (2)
- Hepatitis C (15)
- Global infectious disease threats (4)
- Injecting Drug Use (6)
- Healthy Ageing (1)
- Alcohol and Other Drugs (12)
- Nutrition (1)
